- |||||||||| Aklief (trifarotene) / Galderma
Review, Journal: A Multimodal Approach to Acne-Induced Post-Inflammatory Hyperpigmentation: Trifarotene as a Long-Term Intervention. (Pubmed Central) - Nov 23, 2024
Trifarotene, a novel fourth generation retinoid selective for retinoid acid receptor gamma, is approved for the management of moderate-to-severe facial and truncal acne, with recent data supporting its efficacy in acne-induced hyperpigmentation. The purpose of this paper is to review treatment modalities for post-inflammatory hyperpigmentation and present trifarotene as a novel, evidence-based topical option.
- |||||||||| Aklief (trifarotene) / Galderma
Review, Journal: One Acne (Pubmed Central) - Nov 18, 2024
This narrative review highlights that comprehensive skincare regimens should be used throughout acne patients' journeys to reduce treatment-related irritation, improve treatment outcomes, adherence, and satisfaction, and enhance overall skin quality. Patients with sensitive skin should choose tailored skincare products to maintain skin barrier integrity and restore skin function.
- |||||||||| Winlevi (clascoterone cream 1%) / Cosmo Pharma
Review, Journal: An update on the pharmacological management of acne vulgaris: the state of the art. (Pubmed Central) - Nov 18, 2024
There is a need for a blockbuster acne drug that simultaneously targets the 4 main pathogenic factors involved in the appearance of acne lesions while presenting with minimal side effects. Until such a drug exists, combination therapy will remain the standard of treatment for most acne patients.
- |||||||||| Aklief (trifarotene) / Galderma
Evidence for trifarotene in the management of acne and acne sequelae (Amtrium 1) - Aug 5, 2024 - Abstract #EADV2024EADV_5301;
Addressing these issues will enhance treatment outcomes and patient satisfaction in acne management, emphasizing the importance of tailored approaches in clinical practice. Sponsored by Galderma.
- |||||||||| Aklief (trifarotene) / Galderma
Beyond Active Ingredients: The Impact of Control Arms in Dermatology (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_5160;
These findings accentuate the importance of integrating good skincare habits into patient care strategies, reinforcing that effective skincare alone may account for a significant portion of the overall treatment efficacy. It is imperative for healthcare providers to emphasise to patients the benefits of consistent and proper skincare practices, which can profoundly complement and enhance the results of specific dermatological treatments.
- |||||||||| Aklief (trifarotene) / Galderma
Unlocking the patient perspective: Exploring acne-induced hyperpigmentation in the Phase 4 LEAP study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1803;
Although the LEAP study clinical endpoints did not reach statistical significance at Week 24, the study provided valuable insight into the effect of trifarotene on AIH. These exit interviews offer a deeper understanding of the burden of AIH, perceived changes, and treatment satisfaction from the patient
- |||||||||| Aklief (trifarotene) / Galderma
Review, Journal: An Overview on the Management of Atrophic Acne Scars: The Role of Trifarotene as an Adjunct. (Pubmed Central) - Jul 4, 2024
Recently, data on trifarotene supports its application in acne scarring. Herein, we provide a succinct review on various treatments for acne scarring and explore how trifarotene and its mechanism of action present an additional topical approach to target atrophic acne scarring.
- |||||||||| Aklief (trifarotene) / Galderma
Journal: Editor's Highlights (Pubmed Central) - May 24, 2024
We will also delve into the early and aggressive treatment of HS and highlight a link between HS and increased cardiovascular risk. These insights demand a paradigm shift toward a more proactive and holistic management of HS, integrating skin and systemic health considerations to enhance patient outcomes significantly.
- |||||||||| Aklief (trifarotene) / Galderma
Journal: Trifarotene-based holistic management of acne. (Pubmed Central) - May 24, 2024
These insights demand a paradigm shift toward a more proactive and holistic management of HS, integrating skin and systemic health considerations to enhance patient outcomes significantly. No abstract available
- |||||||||| Winlevi (clascoterone cream 1%) / Cassiopea, Aklief (trifarotene) / Galderma
Retrospective data, Review, Journal: Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis. (Pubmed Central) - May 11, 2024
Along with highlighting the importance of a comprehensive skincare regimen to increase treatment efficacy and adherence, we discuss topical retinoids and retinoid combination options in the acne armamentarium that may be beneficial for sequelae prevention and management, such as adapalene 0.3%? No significant differences in efficacy were observed between clascoterone, trifarotene, and tazarotene after 12
- |||||||||| Winlevi (clascoterone cream 1%) / Cassiopea
Journal: Guidelines of care for the management of acne vulgaris. (Pubmed Central) - Apr 15, 2024
No significant differences in efficacy were observed between clascoterone, trifarotene, and tazarotene after 12 These guidelines provide evidence-based recommendations for the management of acne vulgaris.
- |||||||||| Aklief (trifarotene) / Galderma
PHASE IV STUDIES SHOW TRIFAROTENE IS EFFICACIOUS AND SUITABLE FOR BROAD RANGE OF PATIENT TYPES (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2522;
These findings may guide dermatologists in personalizing retinoid therapy to minimize adverse reactions in specific patient populations. Across a broad range of subject types, trifarotene had good efficacy for improving acne, atrophic scars, and hyperpigmentation, and safety.
- |||||||||| Aklief (trifarotene) / Galderma
TRIFAROTENE SHOWN TO IMPROVE ACNE AND RELATED SEQUELAE (SCARS, PIGMENTATION) (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2519;
Management of atrophic acne scarring and hyperpigmentation is an important consideration in acne therapy. Trifarotene achieved rapid improvements in these acne sequelae along with efficacious acne control.
- |||||||||| Winlevi (clascoterone cream 1%) / Cassiopea
Journal: Drugs for acne. (Pubmed Central) - Jan 31, 2024
Patients described noticeable and meaningful changes in the appearance of PIH and daily life impacts. No abstract available
- |||||||||| Aklief (trifarotene) / Galderma
Trial completion: START: Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation (clinicaltrials.gov) - Sep 18, 2023
P4, N=121, Completed,
Trifarotene was effective and well tolerated in treating moderate-to-severe facial acne and reducing atrophic acne scars, with reduction of total atrophic scar count as early as week 2. Active, not recruiting --> Completed
- |||||||||| Aklief (trifarotene) / Galderma
Efficacy and safety of trifarotene cream 50 (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2261;
P4
PAHPI total facial score and IGA success, respectively, demonstrated numerically and significant advantages for trifarotene treatment. Trifarotene was well-tolerated with a lower incidence of TEAEs compared with the vehicle group across all skin types throughout the study.
- |||||||||| isotretinoin oral / Generic mfg.
Unilateral breast enlargement (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2164;
It seemed to be dose dependent and subsided after lowering the dose of the medication or stopping the treatment. The cause of this phenomenon remains unknown, however dysfunction of retinaldehyde dehydrogenases should be considered as a possible explanation.
- |||||||||| Aklief (trifarotene) / Galderma
Trial completion, Trial primary completion date: Study Comparing Trifarotene Cream, 0.005% To AKLIEF (clinicaltrials.gov) - Aug 24, 2023
P3, N=807, Completed,
The cause of this phenomenon remains unknown, however dysfunction of retinaldehyde dehydrogenases should be considered as a possible explanation. Active, not recruiting --> Completed | Trial primary completion date: Jun 2023 --> Jan 2023
- |||||||||| Aklief (trifarotene) / Galderma
Trifarotene in Context: Exploring the Acne Burden in Latin America () - Jul 3, 2023 - Abstract #WCD2023WCD_4606;
Active, not recruiting --> Completed | Trial primary completion date: Jun 2023 --> Jan 2023 Trifarotene is effective and well tolerated in people with acne, including in subjects with darker FSTs and LatAm subjects
- |||||||||| Aklief (trifarotene) / Galderma
Trifarotene Effects on Acne-Related Gene Expression () - Jul 3, 2023 - Abstract #WCD2023WCD_4605;
Trifarotene is effective and well tolerated in people with acne, including in subjects with darker FSTs and LatAm subjects This study revealed that trifarotene affects both epidermal and immune components of acne pathogenesis
- |||||||||| Aklief (trifarotene) / Galderma
Trial completion, Trial completion date: LEAP: AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation (clinicaltrials.gov) - Dec 21, 2022
P4, N=123, Completed,
In two head-to-head studies comparing the irritation potential of third- and fourth-generation retinoids, tazarotene 0.045% lotion was significantly less irritating than trifarotene 0.005% cream and numerically less irritating than adapalene 0.3% gel. Active, not recruiting --> Completed | Trial completion date: Apr 2023 --> Dec 2022
- |||||||||| Review, Journal: Biphenyls in Clusiaceae: Isolation, structure diversity, synthesis and bioactivity. (Pubmed Central) - Dec 20, 2022
In this review, we summarize the progress and development in the chemistry and biological activity of biphenyls in Clusiaceae, providing an in-depth discussion of their structural diversity and medicinal potential. We also present a preliminary discussion of the biological effects with or without prenyl groups on the biphenyls.
- |||||||||| Aklief (trifarotene) / Galderma
Journal: Novel and emerging treatment options for acne vulgaris (Pubmed Central) - Nov 3, 2022
Recently, in addition to other fixed combinations, a fixed combination of adapalene and benzoyl peroxide that targets acne scars has been made available for the first time. The newly available products and other potentially emerging treatment options will increase the armamentarium of acne therapies and potentially reduce its prevalence worldwide.
- |||||||||| Aklief (trifarotene) / Galderma
Enrollment closed, Trial primary completion date: START: Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation (clinicaltrials.gov) - Oct 17, 2022
P4, N=118, Active, not recruiting,
The newly available products and other potentially emerging treatment options will increase the armamentarium of acne therapies and potentially reduce its prevalence worldwide. Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2022 --> Mar 2023
|
